Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 15/20 | 0.55 |
| ▸ | CALCR | P30988 | 15/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 4/20 | 0.50 |
| ▸ | NPY4R | P50391 | 4/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.50 |
| ▸ | NPY1R | P25929 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222190 | 0.90 | RAMP3 (0.55) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30906337 | 0.87 | RAMP3 (0.55) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29430214 | 0.87 | MAPK8 (0.61) | RAMP3CALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL29679877 | 0.86 | RAMP3 (0.61) | RAMP3CALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL29430209 | 0.85 | MAPK8 (0.64) | RAMP3CALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL29522849 | 0.85 | NPY2R (0.55) | RAMP3CALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL30906534 | 0.85 | RAMP3 (0.55) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29827221 | 0.85 | NPY2R (0.59) | RAMP3CALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL30906369 | 0.84 | RAMP3 (0.57) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30390834 | 0.84 | RAMP3 (0.63) | RAMP3CALCRNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | RAMP3 3010/4885CALCR 3315/4885MAPK8 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.